Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Post-Market Trading 05-20 17:37:14 EDT

18.59

+2.24

+13.70%

盘后18.62

+0.03+0.16%

17:11 EDT

High18.85	Low16.50	Vol130.26K
Open16.55	D1 Closing16.35	Amplitude14.37%
Mkt Cap474.69M	Tradable Cap178.77M	Total Shares25.53M
T/O2.34M	T/O Rate1.35%	Tradable Shares9.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":18.59,"timestamp":1716235200000,"preClose":16.35,"halted":0,"volume":130261,"hourTrading":{"tag":"盘后","latestPrice":18.62,"preClose":18.59,"latestTime":"17:11 EDT","volume":1445,"amount":26863.870730000002,"timestamp":1716239494944},"delay":0,"floatShares":9616210,"shares":25534458,"eps":-7.123353,"marketStatus":"Post-Market Trading","change":2.24,"latestTime":"05-20 17:37:14 EDT","open":16.55,"high":18.85,"low":16.5,"amount":2339252.959939,"amplitude":0.143731,"askPrice":20,"askSize":33,"bidPrice":17.03,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-7.123353,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1716249600000},"marketStatusCode":4,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":16.35,"preHourTrading":{"tag":"盘前","latestPrice":16.35,"preClose":16.35,"latestTime":"09:05 EDT","volume":79,"amount":1295.830048,"timestamp":1716210316605},"postHourTrading":{"tag":"盘后","latestPrice":18.62,"preClose":18.59,"latestTime":"17:11 EDT","volume":1445,"amount":26863.870730000002,"timestamp":1716239494944},"volumeRatio":0.723877},"requestUrl":"/m/hq/s/LENZ/wiki","defaultTab":"wiki","newsList":[{"id":"2437748794","title":"Larimar Therapeutics Shares Up 22%, FDA Lifts Hold for Nervous System Disorder Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2437748794","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2437748794?lang=en_us&edition=fundamental","pubTime":"2024-05-21 04:55","pubTimestamp":1716238500,"startTime":"0","endTime":"0","summary":"Shares of Larimar Therapeutics were trading higher in after-hours action Monday, following news the U.S. Food and Drug Administration has lifted a partial clinical hold on the nomlabofusp program in Friedreich's Ataxia, an inherited disorder of the nervous system.After the bell, the company's stock gained 22% to $8.88. The stock ended the day's regular session with a 1.5% loss, closing at $7.27.The partial clinical hold was removed following a review of data from a recently completed four-week, placebo-controlled Phase 2 dose exploration study, which included data from both 25 mg and 50 mg cohorts.Nomlabofusp is a protein replacement therapy which aims to address the root cause of FA by delivering frataxin to mitochondria, the company said. Larimar also said nomlabofusp was generally well-tolerated during the four-week treatment period, and that patients with quantifiable levels at baseline and Day 14 in the 50 mg cohort saw frataxin levels in skin cells over 33% of the average level s","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2437448271","title":"BRIEF-Larimar Therapeutics Announces FDA Has Removed Partial Clinical Hold For Nomlabofusp Program In Friedreich’S Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2437448271","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2437448271?lang=en_us&edition=fundamental","pubTime":"2024-05-21 04:47","pubTimestamp":1716238029,"startTime":"0","endTime":"0","summary":"May 20  - Larimar Therapeutics Inc   :   * LARIMAR THERAPEUTICS ANNOUNCES FDA HAS REMOVED PARTIAL CLINICAL HOLD FOR NOMLABOFUSP PROGRAM IN FRIEDREICH’S ATAXIA   * INTERIM DATA FROM OLE STUDY REMAINS ON TRACK FOR Q4 2024   * BIOLOGICS LICENSE APPLICATION  SUBMISSION TARGETED FOR 2H 2025   * PLANS TO DOSE ESCALATE TO 50 MG FOLLOWING FURTHER CHARACTERIZATION OF FRATAXIN PHARMACODYNAMICS  AT 25 MG DOSE   * ONGOING OPEN LABEL EXTENSION  STUDY INITIALLY EVALUATING 25 MGSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2437482157","title":"BUZZ-Larimar Therapeutics rises as US FDA removes partial clinical hold on genetic disease therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2437482157","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2437482157?lang=en_us&edition=fundamental","pubTime":"2024-05-21 04:39","pubTimestamp":1716237565,"startTime":"0","endTime":"0","summary":"** Shares of drug developer Larimar Therapeutics    rise 22.6% to $8.91 in late afternoon trading    ** Company says US FDA has removed the partial clinical hold previously placed on its experimental genetic disease therapy    ** LRMR is testing the therapy, nomlabofusp, as a potential treatment of Friedreich's ataxia, a rare inherited disease that causes progressive nervous system damage and movement problems   ** The FDA removed the partial clinical hold after a review of data from co's recently completed four-week mid-stage trial    ** Co says interim data from the ongoing label expansion study is expected in Q4 of 2024    ** Plans to submit a marketing application for the therapy in 2H25    ** Stock up 57.8% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2437846224","title":"Dyne Therapeutics announces underwritten proposed offering of common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2437846224","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437846224?lang=en_us&edition=fundamental","pubTime":"2024-05-21 04:11","pubTimestamp":1716235876,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics (Nasdaq: DYN) commenced an underwritten public offering of $300M of shares of its common stock.\nDyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45M of shares of its common stock. Source: Press Release","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108514-dyne-therapeutics-announces-underwritten-proposed-offering-of-common-stock","is_publish_highlight":false,"gpt_icon":0},{"id":"2437484608","title":"Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2437484608","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2437484608?lang=en_us&edition=fundamental","pubTime":"2024-05-21 04:05","pubTimestamp":1716235500,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May 20, 2024----Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology  indications, today announced the appointment of Troy Ignelzi as an independent member of its Board of Directors and as Chair of the Audit Committee. Mr. Ignelzi brings nearly two decades of financial leadership and industry experience to Contineum’s board.\"I am extremely pleased to welcome Troy to the Contineum board. Troy’s recent public markets experience, coupled with his proven track record in building and financing precision neuroscience companies, will be invaluable to us as we seek to advance our pipeline of NI&I therapies toward patients in need,\" said Carmine Stengone, Chief Executive Officer of Contineum.Contineum Therapeutics  is a clinical stage biopharmaceutica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/contineum-therapeutics-announces-appointment-troy-200500341.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437869484","title":"Dyne Therapeutics Announces Proposed Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2437869484","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2437869484?lang=en_us&edition=fundamental","pubTime":"2024-05-21 04:01","pubTimestamp":1716235260,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May 20, 2024  -- Dyne Therapeutics,Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne.This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/P82nHIfwCHpG622_bmCMSg--~B/aD00NDc7dz0xNDc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c24d5b28ef01b702599d83452a9a1c63","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/P82nHIfwCHpG622_bmCMSg--~B/aD00NDc7dz0xNDc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c24d5b28ef01b702599d83452a9a1c63"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dyne-therapeutics-announces-proposed-public-200100107.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437832374","title":"Dyne Therapeutics Is Maintained at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2437832374","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2437832374?lang=en_us&edition=fundamental","pubTime":"2024-05-21 01:42","pubTimestamp":1716226920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DYN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 20, 2024 13:42 ET (17:42 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2437410091","title":"Dyne Therapeutics Shares Rise 23% on Favorable Drug Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2437410091","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2437410091?lang=en_us&edition=fundamental","pubTime":"2024-05-21 00:38","pubTimestamp":1716223080,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics shares rose 23% Monday after the company reported favorable clinical data for DYNE-101 and DYNE-251 and said it continues to pursue expedited approval for both drugs based on recent regulatory interactions.Shares were recently at $34.01 and are up about 56% this year.The company reported Phase 1/2 data for DYNE-101 in patients with myotonic dystrophy type 1 and Phase 1/2 data for DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. Dyne said new data from both trials \"demonstrated compelling impact on key disease biomarkers as well as improvement in multiple functional endpoints and favorable safety profiles.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2436109691","title":"BUZZ- Dyne Therapeutics jumps on positive data for muscle disorder drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2436109691","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436109691?lang=en_us&edition=fundamental","pubTime":"2024-05-20 22:21","pubTimestamp":1716214883,"startTime":"0","endTime":"0","summary":"** Shares of drug developer Dyne Therapeutics    rise 25.3% to $34.83    ** Co says its experimental drug to treat myotonic dystrophy type 1 , DYNE-101, showed benefit in an early-mid-stage study      ** DM1 is a rare, progressive genetic disease that affects skeletal, cardiac muscle   ** Says its investigational drug being tested for Duchenne muscular dystrophy ,  DYNE-251, helped achieve higher levels of dystrophin protein compared to standard-of-care -DYN     ** DMD is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of dystrophin that help keep muscle cells intact    ** DYN expects to pursue expedited approvals for both programs with an update on registrational pathways expected by year-end   ** \"Given both the data, we believe Dyne is well positioned for an accelerated approval pathway for both the programs,\" H.C. Wainwright analyst Andrew Fein wrote in a note       ** Brokerage hikes PT on co to $48 from $36   ** Including se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2436827105","title":"BRIEF-Coya Therapeutics Announces $5 Million Strategic Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2436827105","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436827105?lang=en_us&edition=fundamental","pubTime":"2024-05-20 21:27","pubTimestamp":1716211648,"startTime":"0","endTime":"0","summary":"May 20 (Reuters) - Coya Therapeutics Inc   :   * COYA THERAPEUTICS ANNOUNCES $5 MILLION STRATEGIC INVESTMENT BY THE ALZHEIMER’S DRUG DISCOVERY FOUNDATION (ADDF)Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2436403103","title":"BRIEF-Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute","url":"https://stock-news.laohu8.com/highlight/detail?id=2436403103","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436403103?lang=en_us&edition=fundamental","pubTime":"2024-05-20 21:23","pubTimestamp":1716211402,"startTime":"0","endTime":"0","summary":"May 20  - eFFECTOR Therapeutics Inc   :   * EFFECTOR THERAPEUTICS TO COLLABORATE WITH THE DANA-FARBER CANCER INSTITUTE ON AN INVESTIGATOR-SPONSORED PHASE 2 CLINICAL TRIAL EVALUATING ZOTATIFIN AS COMBINATION TREATMENT IN ER+ ENDOMETRIAL CANCER AND IN LOW GRADE SEROUS OVARIAN CANCER   * EFFECTOR THERAPEUTICS : ANTICIPATE DETERMINATION OF PHASE 2 DOSE  OF ZOTATIFIN IN COMBINATION WITH FULVESTRANT & ABEMACICLIB, IN H2 2024Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2436010347","title":"BRIEF-Lisata Therapeutics Receives Paediatric Investigation Plan Waiver From European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2436010347","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436010347?lang=en_us&edition=fundamental","pubTime":"2024-05-20 21:22","pubTimestamp":1716211364,"startTime":"0","endTime":"0","summary":"May 20  - Lisata Therapeutics Inc   :   * LISATA THERAPEUTICS RECEIVES PAEDIATRIC INVESTIGATION PLAN WAIVER FROM THE EUROPEAN MEDICINES AGENCY FOR CERTEPETIDE IN PANCREATIC CANCER   * LISATA THERAPEUTICS INC - WAIVER CONFIRMS THAT PAEDIATRIC STUDIES OF CERTEPETIDE IN PANCREATIC CANCER ARE NOT NEEDEDSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2436346103","title":"Dyne Therapeutics announces data from early stage trials of muscular dystrophy treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2436346103","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436346103?lang=en_us&edition=fundamental","pubTime":"2024-05-20 21:06","pubTimestamp":1716210390,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics  announced positive data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.  New data from both trials demonstrated compelling impact on key disease biomarkers, and improvement in multiple functional endpoints and favorable safety profiles. In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months In Phase 1/2 DELIVER Trial, DYNE-251 Showed 3.2% Mean Unadjusted Dystrophin Expression at 6 Months in 10 mg/kg Cohort Administered Monthly; 10 Times Higher Level of Dystrophin Than Reported for Weekly Administered Standard of Care Favorable Safety Profiles for DYNE-101 and DYNE-251 with Enrollment Complete in the 6.8 mg/kg Cohort of ACHIEVE and 40 mg/kg Cohort of DELIVER Source: Press Release","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108309-dyne-therapeutics-announces-data-from-early-stage-trials-of-muscular-dystrophy-treatments","is_publish_highlight":false,"gpt_icon":0},{"id":"2436719108","title":"BRIEF-Inhibikase Therapeutics Announces Pricing Of Registered Direct Offering And Warrant Inducement, Priced At-The-Market For Aggregate Gross Proceeds Of $4.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2436719108","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436719108?lang=en_us&edition=fundamental","pubTime":"2024-05-20 21:01","pubTimestamp":1716210100,"startTime":"0","endTime":"0","summary":"May 20  - Inhibikase Therapeutics Inc   :   * INHIBIKASE THERAPEUTICS ANNOUNCES PRICING OF REGISTERED DIRECT OFFERING AND WARRANT INDUCEMENT, PRICED AT-THE-MARKET FOR AGGREGATE GROSS PROCEEDS OF $4.0 MILLION   * INHIBIKASE SETS WARRANTS EXERCISE PRICE AT $1.68   * INHIBIKASE THERAPEUTICS- ENTERED A SECURITIES PURCHASE AGREEMENT WITH A SINGLE INSTITUTIONAL INVESTOR TO PURCHASE 1.7 MILLION SHARES OF COMMON STOCKSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2436915108","title":"BRIEF-Allarity Therapeutics Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2436915108","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436915108?lang=en_us&edition=fundamental","pubTime":"2024-05-20 21:00","pubTimestamp":1716210024,"startTime":"0","endTime":"0","summary":"May 20 (Reuters) - Allarity Therapeutics Inc   :   * ALLARITY THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ'S MINIMUM STOCKHOLDERS' EQUITY REQUIREMENTSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2436170146","title":"Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2436170146","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2436170146?lang=en_us&edition=fundamental","pubTime":"2024-05-20 20:30","pubTimestamp":1716208200,"startTime":"0","endTime":"0","summary":"Data follow the approval of the world's first self-amplifying  COVID-19 vaccine for adults in Japan.These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating longer duration of immunity compared to traditional COVID-19 mRNA vaccine booster.KING OF PRUSSIA, Pa. and SAN DIEGO, May 20, 2024 /PRNewswire/ --Global biotechnology leaderCSL  and Arcturus Therapeutics  today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying  COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.The results demonstrate that two 5 μg doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19. The efficacy of ARCT-154 against severe COVID-19 ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0yTvG6RCLk9Hr.kDeMk9aA--~B/aD0zNDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f57d6417ee02a6b52d9a87c500485e01","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0yTvG6RCLk9Hr.kDeMk9aA--~B/aD0zNDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f57d6417ee02a6b52d9a87c500485e01"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nature-communications-publishes-pivotal-data-123000941.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nature-communications-publishes-pivotal-data-123000941.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2436703311","title":"Coya Therapeutics reports $5M strategic investment by ADDF","url":"https://stock-news.laohu8.com/highlight/detail?id=2436703311","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436703311?lang=en_us&edition=fundamental","pubTime":"2024-05-20 20:28","pubTimestamp":1716208097,"startTime":"0","endTime":"0","summary":"Coya Therapeutics  Monday said that the Alzheimer’s Drug Discovery Foundation has purchased 603,136 shares of the company’s common stock at a purchase price of $8.29 a piece, for an aggregate investment of $5 million. Coya’s lead therapeutic candidate, COYA 302, is being evaluated in multiple neurodegenerative diseases, including FTD, and the company intends for this equity investment to help fund the development of COYA 302 in a planned Phase 2 trial in FTD.  \"Inflammation has emerged as a promising novel pathway for chronic neurological diseases like FTD. A combination drug, like COYA 302, is an innovative approach being developed to suppress neuroinflammation by targeting multiple inflammatory pathways,\" said Howard Fillit, M.D., Co-Founder and Chief Science Officer of the ADDF. Source: Press Release","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1354171846/image_1354171846.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1354171846/image_1354171846.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108264-coya-therapeutics-reports-5m-strategic-investment-by-addf","is_publish_highlight":false,"gpt_icon":0},{"id":"2436177720","title":"Autolus Therapeutics: A Strong Buy on Promising Obe-cel Developments and Strategic Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2436177720","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2436177720?lang=en_us&edition=fundamental","pubTime":"2024-05-20 20:27","pubTimestamp":1716208071,"startTime":"0","endTime":"0","summary":"Analyst Kelly Shi of Jefferies maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target of $11.00. Kelly Shi h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/autolus-therapeutics-a-strong-buy-on-promising-obe-cel-developments-and-strategic-readiness?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/autolus-therapeutics-a-strong-buy-on-promising-obe-cel-developments-and-strategic-readiness?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2436177973","title":"BRIEF-Ptc Therapeutics Inc Announces European Commission Returns Translarna™ Opinion To CHMP For Re-Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2436177973","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436177973?lang=en_us&edition=fundamental","pubTime":"2024-05-20 20:16","pubTimestamp":1716207390,"startTime":"0","endTime":"0","summary":"PTC Therapeutics Inc   :   * PTC THERAPEUTICS INC: ANNOUNCES EUROPEAN COMMISSION RETURNS TRANSLARNA OPINION TO CHMP FOR RE-EVALUATION   * PTC THERAPEUTICS INC: 2024 REVENUE GUIDANCE PAUSED   * PTC THERAPEUTICS INC: TRANSLARNA AUTHORIZATION REMAINS ACTIVE IN EUROPE   * PTC THERAPEUTICS INC: EUROPEAN COMMISSION DECIDES AGAINST ADOPTION OF NEGATIVE OPINIONSource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2436399170","title":"Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2436399170","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2436399170?lang=en_us&edition=fundamental","pubTime":"2024-05-20 20:15","pubTimestamp":1716207300,"startTime":"0","endTime":"0","summary":"Funds will help support the development of COYA 302 for the treatment of Frontotemporal Dementia . COYA 302’s combination therapeutic approach aligns with ADDF’s belief in combination therapy being the future of Alzheimer’s and related dementia treatments. The ADDF’s mission is to rapidly accelerate the development of drugs to prevent, treat, and cure Alzheimer’s disease  and related dementias, including FTD. Coya’s lead therapeutic candidate, COYA 302, is being evaluated in multiple neurodegenerative diseases, including FTD, and the Company intends for this equity investment to help fund the development of COYA 302 in a planned Phase 2 trial in FTD.Dr. Berman added, \"Research has shown that neurodegenerative diseases, such as AD, FTD, Parkinson’s disease, and ALS, aka ‘Lou Gehrig’s disease,’ share common disease pathways, including neuroinflammation and catastrophic neuronal loss that leads to cognitive or motor dysfunction through the complex interplay of the body’s immune system and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-announces-5-million-121500651.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://lenz-tx.com","stockEarnings":[{"period":"1week","weight":0.0394},{"period":"1month","weight":-0.0763},{"period":"3month","weight":-0.2317},{"period":"6month","weight":0.0025},{"period":"1year","weight":-0.1833},{"period":"ytd","weight":-0.1085}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license  agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.187611},{"month":2,"riseRate":0.666667,"avgChangeRate":0.15153},{"month":3,"riseRate":0,"avgChangeRate":-0.19103},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.06634},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.164965},{"month":6,"riseRate":0.5,"avgChangeRate":0.042853},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.062127},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.052314},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.028796},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.037137},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.124883},{"month":12,"riseRate":0.666667,"avgChangeRate":0.157581}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction